braf mutations in nsclc - 2022 program: targeted therapies forum
Published 1 year ago • 58 plays • Length 6:57Download video MP4
Download video MP3
Similar videos
-
1:36
braf and ntrk inhibitors: their role in early nsclc - 2022 program: targeted therapies forum
-
6:30
braf disease: braf/mek combo in other mutations - 2022 program: targeted therapies forum
-
2:45
kras mutations in advanced nsclc - 2022 program: targeted therapies forum - english
-
4:56
first line therapy for braf and ntrk nsclc - 2022 program: targeted therapies forum
-
4:02
treatment of egfr mutated nsclc - 2022 program: targeted therapies forum - english
-
5:44
braf/mek combination in braf v600e disease - 2022 program: targeted therapies forum
-
6:13
evolving treatment for nsclc: targeted therapies - 2022 program: targeted therapies forum
-
3:56
how to identify ret nsclc - 2022 program: targeted therapies forum
-
6:05
what are ntrk mutations? - 2022 program: targeted therapies forum
-
3:06
prevalence of targeted driver mutations in nsclc - 2022 program: targeted therapies forum - english
-
7:20
treatment of her2 nsclc - 2022 program: targeted therapies forum
-
3:20
egfr mutated nsclc disease progression on osimertinib - 2022 program: targeted therapies forum
-
7:27
trials in her2 nsclc - 2022 program: targeted therapies forum
-
1:57
alk nsclc: what does it mean? - 2022 program: targeted therapies forum
-
3:34
ret nsclc: a case study - 2022 program: targeted therapies forum
-
7:53
ret nsclc treatment options - 2022 program: targeted therapies forum
-
2:49
treatments for ret nsclc: selpercatinib vs. pralsetinib - 2022 program: targeted therapies forum
-
2:43
ros1 nsclc: is it possible to develop a second mutation? - 2022 program: targeted therapies forum
-
5:35
gracecast - what is the optimal treatment for patients with advanced nsclc and a braf-v600e mutation